Lupin Moves Into Russia With Biocom Buy
This article was originally published in PharmAsia News
Lupin has snapped up the Russian generic firm, ZAO Biocom, sticking to its stated intent of M&A being one of the key drivers of its future as a global generic and specialty company.
You may also be interested in...
Lupin reported a strong set of numbers for the first quarter ended June and expects US sales of its generic version of Glumetza (metformin HCL extended-release tablets) to stay a key contributor despite imminent competition from Sun Pharma, among others. The Indian firm, though, appears to be re-evaluating its Russian acquisition.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?